HSUAN-LING LIAO: Open Payments
NPI 1548914591 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,694 in 80 payments from 15 companies in 2025. Trend: 2023 $1,518 · 2024 $1,467 · 2025 $1,694
Food & beverage: $1,610Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $476 |
| Gilead Sciences, Inc. | 13 | $284 |
| Janssen Biotech, Inc. | 9 | $227 |
| Ardelyx, Inc. | 5 | $112 |
| Celltrion USA Inc. | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Braintree Laboratories, Inc. | 2 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $60 |
| Intercept Pharmaceuticals, Inc. | 2 | $52 |
| VIVUS LLC | 2 | $50 |
Products named: TREMFYA, RINVOQ, LINZESS, Livdelzi, IBSRELA, VEGZELMA, ENTYVIO, SKYRIZI.
Industry payments across CA — which companies pay providers there.
